MK-3795
Phase 2Small molecule
Merck & Co.MK-3795 is one of 55 small molecule programs targeting Von Hippel-Lindau Disease. It is currently in Phase 2.
2
Indications
2
Total Trials
1
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
363 competitors in Renal Cell Carcinoma
#DrugCompanyPhaseTrials
1Cabometyx
Bristol-Myers SquibbPhase 3
Votrient
NovartisPhase 3
Nexavar
BayerPhase 3
Lenvima
EisaiPhase 3
Inlyta
PPrism Pharmaceuticals
Phase 3
Tecentriq
RochePhase 3
Welireg
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Imjudo
AstraZenecaPhase 3
Imfinzi
AstraZenecaPhase 3
Depo-Provera
Eli LillyPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Von Hippel-Lindau Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MK-3795. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company